Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rotavirus VP7 is a 37-kDa glycoprotein that forms the outer layer of the rotavirus capsid and is the primary determinant of the virus's G-serotype (UniProt: P04502). The G4 serotype is one of the most prevalent strains causing severe diarrhea in infants and young children worldwide (PubMed: 15103154). VP7 is essential for the structural integrity of the virion and facilitates the calcium-dependent attachment and penetration of the virus into host intestinal cells (PubMed: 11831707). Because it is a major target for neutralizing antibodies, the VP7 G4 antigen is a critical component of live-attenuated vaccines like RotaTeq (FDA: RotaTeq Label). Vaccination induces a protective immune response that significantly reduces the incidence of severe rotavirus-associated gastroenteritis and related hospitalizations (CDC: Rotavirus Vaccination).
Vaccines containing the VP7 G4 antigen induce the production of serotype-specific and cross-reactive neutralizing antibodies that block viral entry into host enterocytes (PubMed: 15103154).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rotavirus outer capsid glycoprotein VP7 (G4 serotype) (VP7 G4).